Hikma is a discounted “value in complexity” play: supply-reliable sterile injectables and MENA dominance offset a near-term margin trough and legal/geopolitical overhangs.
Overview
Hikma Pharmaceuticals is a FTSE 250-listed multinational drug manufacturer with a diversified three-segment model—Injectables, Branded (MENA), and Hikma Rx (US generics)—and a dual-shore footprint spanning North America and MENA. In 2025, North America generated ~59% of core revenue, MENA ~32.5%, and Europe/ROW ~8.5%, giving the Group both developed-market scale and emerging-market growth exposure. The company’s differentiator is supply reliability and manufacturing quality in sterile injectables, a category frequently impacted by shortages, which allows Hikma to win long-term institutional contracts and take share when competitors face regulatory disruptions. Financially, 2025 delivered solid growth (core revenue ~$3.35B, +~7% reported) but the market punished a sharp Injectables margin decline (35.3% → 31.0%) and guidance for further compression in 2026 (27–28%). Branded MENA and improving Hikma Rx margins partially offset this pressure. With valuation multiples at multi-year lows, an active $250M buyback, and clear medium-term catalysts (Bedford ramp, CMO scaling, and a pivotal US Supreme Court “skinny label” case), Hikma presents an execution-dependent recovery story built on “value in complexity.”